General Information
Company Name
IMMPLACATE
Founded Year
2017
Location (Offices)
Founders / Decision Makers
Number of Employees
2
Industries
-
Funding Stage
-
Social Media

IMMPLACATE - Company Profile

IMMPLACATE is a preclinical stage cell therapy company focusing on developing educated mesenchymal cells (EMCs) for the treatment of unwanted immune responses. The company's pioneering approach aims to address the unmet needs of patients with acute and chronic immune disorders, who face heightened mortality risks and diminished quality of life. Furthermore, the limitations and potential risks associated with current pharmaceutical options underscore the urgency for innovative and safer alternatives. Founded in 2017, IMMPLACATE's mission revolves around leveraging science-based EMC therapy to enhance the wellbeing of individuals battling immune-related conditions. However, detailed information regarding specific industries, headquarters, past investments, and notable investors is currently unavailable.

Funding Rounds & Investors of IMMPLACATE (0)

View All

There is no investment information

Latest News of IMMPLACATE

View All

No recent news or press coverage available for IMMPLACATE.

Similar Companies to IMMPLACATE

View All
Neuronity - Similar company to IMMPLACATE
Neuronity Transforming neurodegenerative disease treatments with innovative immune therapies